Under-the-Tongue Treatment for Food Allergy: New Peanut Allergy Tablet Proves Safe in Early Trial Results
Peanut allergy affects millions of children worldwide, often persisting lifelong and carrying the risk of severe reactions. Current management relies heavily on strict avoidance, but immunotherapy options are evolving.
Exciting early data from the ALLIANCE trial suggest a once-daily peanut SLIT tablet is well-tolerated in children, adolescents, and adults. In the open-label phases, most participants handled dose increases with only mild, local side effects like mouth itching - far fewer systemic issues than seen in some other therapies, and no serious events requiring epinephrine or causing study halts.
This study highlights a potentially easier, home-based approach compared to oral immunotherapy.
References: